Mechanics Financial Corp Acquires 1,102 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Mechanics Financial Corp has increased its holdings in Thermo Fisher Scientific Inc. by 53.9%, acquiring an additional 1,102 shares, bringing their total to 3,148 shares worth approximately $1.28 million.
• Insider transactions show executives sold a total of 30,066 shares valued at over $14 million in the last 90 days, with the EVP selling 400 shares at about $480 each.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43 per share, representing a yield of 0.3% and an annual payout of $1.72.

Mechanics Financial Corp increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 53.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 3,148 shares of the medical research company's stock after acquiring an additional 1,102 shares during the period. Mechanics Financial Corp's holdings in Thermo Fisher Scientific were worth $1,276,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Intergy Private Wealth LLC lifted its stake in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after acquiring an additional 23 shares during the last quarter. Root Financial Partners LLC increased its holdings in Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock worth $252,000 after purchasing an additional 24 shares during the period. Rossmore Private Capital increased its holdings in Thermo Fisher Scientific by 0.5% during the 1st quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after purchasing an additional 24 shares during the period. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its holdings in Thermo Fisher Scientific by 3.1% during the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company's stock worth $326,000 after purchasing an additional 24 shares during the period. 89.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Down 1.1%

Shares of TMO stock opened at $525.07 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $611.49. The stock's fifty day moving average price is $481.27 and its 200 day moving average price is $447.60. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $198.27 billion, a price-to-earnings ratio of 30.37, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analysts Set New Price Targets

Several research analysts have commented on the company. William Blair assumed coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating on the stock. Barclays raised their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a report on Thursday. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.